LITHIUM SALTS IN EXPERIMENTAL ONCOLOGY (REVIEW)
Iuliya Sergeevna TASKAEVA1,2, Nataliya Petrovna BGATOVA1
1Research Institute of
Clinical and Experimental Lymphology - Branch of Federal Research Center
Institute of Cytology and Genetics of SB RAS
2Novosibirsk State
University
Keywords: экспериментальная онкология, соли лития, GSK-3ОІ, IMPase, апоптоз, аутофагия, experimental oncology, lithium salts, GSK-3ОІ, IMPase, apoptosis, autophagy
Abstract
Recently, lithium salts
have been considered as potential compounds for targeted therapy that
can reduce tumor growth. There are a large number of publications
indicating the effects of lithium on the signaling pathways used by
tumor cells for growth and development, and have demonstrated that
lithium can be used as antitumor agent in experimental oncology. The
promise of using lithium salts to develop anticancer drugs is related to
the fact that lithium has 2 main intracellular targets: glycogen
synthase kinase-3β (GSK-3β) and inositol monophosphatase (IMPase), the
inhibition of which by lithium can induce cancer cell death by apoptosis
or autophagy. Lithium has been shown to block the proliferation of
cancer cells by cell cycle arrest in the G2 /M phase, and
also stimulates apoptosis and autophagy in cancer cells. This review
summarizes data on the transport of lithium across cell membranes,
characterizes its main intracellular targets and presents the results of
studies in which lithium was used in experimental cancer therapy of
various localization with an emphasis on signaling pathways used by
cancer cells for growth and metastasis.
|
